A clinical analysis from the Bio ImPAcT Consortium reports that Ireland is missing major savings opportunities due to low biosimilar adoption in oncology. While biosimilars account for about 52% to 54% of oncology biologics in Ireland, national uptake lags peers such as Austria, the Netherlands, and Norway, where penetration is consistently above 90%. The paper links adoption gaps to financial toxicity and constrained patient access, arguing that policy design and implementation are the primary levers rather than product-level limitations. It frames the issue against rising oncology spend projections globally and growing clinical demand. For payer and access stakeholders, the report provides quantitative context for why biosimilar scaling strategies—especially reimbursement and prescribing incentives—remain a central operational challenge.